The Pharma Data

MARCH 15, 2022

CRSwNP CRSwNP is characterised by persistent inflammation of the mucous membrane lining the nasal passages and sinuses accompanied by benign growths, called nasal polyps. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Trials 52

Trials Medicine Licensing Licensing 52

The Pharma Data

SEPTEMBER 9, 2021

2 Inflammation is a distinctive feature of asthma 3 and plays a key role in asthma symptoms, 4 exacerbations 5 and deaths. Many millions of patients globally rely on their rescue inhaler to alleviate acute symptoms, but this does not treat the underlying inflammation in asthma. AstraZeneca in Respiratory & Immunology.

Trials 52

Trials Medicine Allergies Dermatology 52

Pfizer

SEPTEMBER 27, 2022

We need YOU to design for science! We need YOU to design for science! More of us than ever need science to restore not just the health of our loved ones, but life as we remember it. The  The power of science is the key to unlocking the answers to the world’s most challenging medical questions. Calling All Creatives!

Medicine 52

Medicine Vaccination Vaccine Licensing 52

Drug Discovery World

JANUARY 15, 2024

Evotec and Owkin In another strategic collaboration, Evotec has agreed an AI-powered integrated multi-target collaboration in oncology, immunology and inflammation with techbio Owkin. Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD.

Drugs 59

Drugs Licensing Licensing Protein 59

XTalks

MARCH 28, 2024

Chronic pelvic pain: Pain experienced outside of menstrual periods and affecting the lower back and pelvic area. The targeted therapy treatment approach requires understanding the effects of endometriosis at both molecular and immunological levels. This condition is known to affect an estimated one in ten women of reproductive age.

Hormones 40

Hormones Life Science In-Vitro Drugs 40

The Pharma Data

OCTOBER 9, 2021

Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. STELARA is the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, both of which play an important role in inflammation associated with immune-mediated diseases like PsA.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

pharmaphorum

MAY 18, 2022

One research-driven company with a strong patient focus in neurology is UCB. “In With its 20-plus year legacy in creating an understanding of this complex disease and the heterogeneous population it affects, UCB went from an initial focus on arresting the symptoms to stopping seizures from happening altogether.

Gene Therapy 81

Gene Therapy Gene Genetics Development 81

The Pharma Data

NOVEMBER 18, 2021

Varon, Vice President, Health Economics and Outcomes Research, Immunology, AbbVie.”In It can also beget some people to witness problems in other areas of the body, or further general symptoms similar as fatigue.10 ” Achieving RA absolution was plant to give 19-52 savings in direct medical costs (e.g., About AbbVie.

Production 52

Production Drugs Research 52

The Pharma Data

MARCH 30, 2021

Rodeo’s 15-PGDH program is a strong strategic fit with Amgen’s inflammation portfolio and efforts to develop first-in-class therapeutics for patients. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives.

Life Science 52

Life Science Development Manufacturing Genetics 52

Pharma Marketing Network

APRIL 27, 2021

He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition with Professor W.C. He also served as Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global R&D facility.

Medicine 52

Medicine Allergies Research Development 52

pharmaphorum

JANUARY 15, 2023

Neurological conditions like Multiple Sclerosis (MS) are an incredibly important area of research when it comes to drug discovery, but under that (sometimes mistaken) umbrella diagnosis occur other, rarer diseases, such as Neuromyelitis Optica Spectrum Disorder (NMOSD). Well, science is something that takes time,” Patterson reasoned.

Antibody 102

Antibody Genetics Medicine Drugs 102

The Pharma Data

MARCH 23, 2022

Biologics are a class of prescription treatments that block specific parts of the immune system responsible for inflammation and causing plaque PsO and its symptoms when overactive in the body.6 professor of clinical dermatology and vice-chair for diversity and inclusion at Weill Cornell Medicine in New York and lead study investigator.b “By

Dermatology 52

Dermatology Clinical Research Research Medicine 52

The Pharma Data

OCTOBER 9, 2021

2 In addition to eosinophils, other cells including mast cells, T-cells and fibroblasts drive injury, inflammation and detrimental tissue remodelling. 2 In addition to eosinophils, other cells including mast cells, T-cells and fibroblasts drive injury, inflammation and detrimental tissue remodelling.

Drugs 52

Drugs Sales Medicine Dermatology 52

The Pharma Data

MARCH 3, 2021

Symbicort (budesonide/formoterol) is a combination formulation containing budesonide, an inhaled corticosteroid that treats underlying inflammation, and formoterol, a long-acting beta2-agonist bronchodilator with a fast onset of action, in a single inhaler. AstraZeneca in Respiratory & Immunology.

Dermatology 52

Dermatology Drug Delivery Medicine Containment 52

The Pharma Data

MARCH 29, 2022

* Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets. IGM to receive $150 million upfront payments, potentially over $6 billion in aggregate development, regulatory and commercial milestones.

Antibody 52

Antibody Engineer Development Manufacturing 52

The Pharma Data

JULY 8, 2021

2,3,6 Due to the complexity of severe asthma, many patients have unclear or multiple drivers of inflammation and may not qualify for or respond well to a current biologic medicine. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Trials 52

Trials Medicine Sales Clinical Trials 52

The Pharma Data

JULY 29, 2021

Looking forward, we remain highly confident in our ability to achieve at least a 6% compound annual growth rate through 2025 and intend to build upon our recent successes by continuing to follow the science, trust in our people and remain focused on delivering breakthroughs for the patients we serve.”.

Manufacturing 52

Manufacturing Sales Contract Manufacturing Vaccination 52

XTalks

DECEMBER 4, 2020

Since CKD is a broad diagnosis that can have a variety of underlying causes, a beneficial focus of current research strategies has been to identify biomarkers and develop diagnostics that can help stratify patients into clinically relevant categories and help guide their management. GFR adjusted for body surface area (BSA).

Trials 52

Trials Clinical Trials Clinical Trials Antibody 52

Drug Discovery World

APRIL 15, 2024

Reece Armstrong speaks to Sean McClain , Founder & CEO of Absci about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. From Consulting to Industry.

Scientist 52

Scientist In-Vitro Research Life Science 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. In the third quarter of 2022, the company underwent several more organizational changes to better leverage expertise in key areas. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

SEPTEMBER 15, 2020

Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. THERAPEUTIC AREAS OF FOCUS. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

DECEMBER 15, 2020

Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. Scientists will be testing a drug class targeting the C-reactive protein (CRP) marker of acute inflammation in the body. The researchers regulated the abnormal immunological memory processes found in these patients.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

Pfizer

OCTOBER 28, 2022

1,2,3 As the developer of tofacitinib, Pfizer is committed to advancing the science of Janus kinase inhibition and enhancing understanding of tofacitinib through robust clinical development programs in the treatment of immune-mediated inflammatory conditions. Consider yearly screening for patients in highly endemic areas for TB.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

JULY 21, 2021

Actemra/RoActemra: 3 Roche’s intravenous anti-inflammation medicine received FDA Emergency Use Authorization (EUA) for the treatment of severe COVID-19 in hospitalised adults and children. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. About Roche.

Sales 52

Sales Medicine Antibody In-Vitro 52

The Pharma Data

JUNE 16, 2021

“The study builds on the hypothesis that JAK inhibition could mitigate systemic and alveolar inflammation in patients with COVID-19-related pneumonia.”. “To Chief Medical Officer, Pfizer Inflammation & Immunology. “As Viral reactivation including herpes virus and hepatitis B reactivation have been reported. Pfizer Inc.:

Medicine 40

Medicine Clinical Trials Clinical Trials Trials 40

The Pharma Data

MAY 4, 2021

Frank D’Amelio, Chief Financial Officer and Executive Vice President, Global Supply, stated: “I am very happy with the performance of all of our therapeutic areas this quarter. Inflammation & Immunology. to help protect adults and children who are visiting or living in TBE endemic areas. Rare Disease. Total Revenue.

Vaccination 40

Vaccination Vaccine Production Sales 40